Pharmacogenetics, adverse drug reactions and public health

Community Genetics

Volumn 9, Issue 1, 2006, Pages 50-54

  Kollek, Regine ^a,b   Van Aken, Jan ^a   Feuerstein, Günter ^a   Schmedders, Mechtild ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b FSP Biotechnik Gesellschaft und Umwelt ^*  (Germany)

Author keywords

Adverse drug reactions; Pharmacogenetics; Public health; Testing

Indexed keywords

ANTIDEPRESSANT AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOSTATIC AGENT; HALOPERIDOL; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; METOPROLOL; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; THIOPURINE METHYLTRANSFERASE;

BRADYCARDIA; CHRONIC INFLAMMATION; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; HEALTH SURVEY; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERACTIVITY; HYPERTENSION; HYPOTENSION; ISCHEMIA; LEUKOPENIA; LIVER TOXICITY; LYMPHATIC LEUKEMIA; META ANALYSIS; ORGAN TRANSPLANTATION; PHARMACOGENETICS; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA;

6-MERCAPTOPURINE; ADRENERGIC BETA-ANTAGONISTS; ANTIPSYCHOTIC AGENTS; HALOPERIDOL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METOPROLOL; PHARMACOGENETICS; PUBLIC HEALTH;

EID: 33344471159     PISSN: 14222795     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090693     Document Type: Conference Paper

References (22)

1. Abbott A: With your genes? Take one of these, three times a day. Nature 2003;425:760-762.
2. Schneeweiss S, Hasford J, Göttler M, et al: Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol 2002;58:285-291.
3. Schönhöfer PS, Lelgemann M, von Maxen A, Wille H: Häufigkeit von Arzneimittelrisiken und Risikokommunikation; in Hart D, Kemmnitz W, Schnieders C (eds): Arzneimittelrisiken: Kommunikation und Rechtsverfassung. Baden-Baden, Nomos, 1998, pp 109-120.
4. Schnurrer JU, Frölich JC: Zur Häufigkeit und Vermeidbarkeit von tödlichen unerwünschten Arzneimittelwirkungen. Internist 2003;44:889-895.
5. Mancinelli L, Cronin M, Sadee W: Pharmacogenomics: the promise of personalised medicine. AAPS Pharmsci 2000;2:4.
6. Weinshilboum R: Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 2001;29:601-605.
7. Kollek R, Feuerstein G, Schmedders M, van Aken J: Pharmakogenetik: Implikationen für Patienten und Gesundheitswesen. Baden-Baden, Nomos, 2004.
8. van Aken J, Schmedders M, Feuerstein G, Kollek R: Prospects and limits of pharmacogenetics: the thiopurine methyl transferase (TPMT) experience. Am J Pharmacogenomics 2003;3:149-155.
9. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, et al: Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-1030.
10. Schwabe U, Paffrath D: Arzneiverordnungsreport 2002. Berlin, Springer, 2003.
11. Wuttke H, Rau T, Heide R, et al: Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002;72:429-437.
12. Pirmohamed M, Park BK: Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology 2003;192:23-32.
13. Wuttke H, Rau T, Eschenhagen T: Genpolymorphismen in Arzneimittel- abbauenden Enzymen. Bedeutung für die Therapie mit β-Blockern. Dtsch Med Wochenschr 2004;129:831-835.
14. Schwabe U, Paffrath D: Arzneiverordnungsreport 1999. Berlin, Springer, 2000.
15. Brockmöller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Müller-Oerlinghausen B, Roots I: The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002;72:438-452.
16. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, et al: Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27:105-119.
17. Meisel C, Roots I, Cascorbi I, Brinkmann U, Brockmöller J: How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport. Clin Chem Lab Med 2000;38:869-876.
18. Lesko LJ, Woodcock J: Pharmacogenomic-guided drug development: regulatory perspective. Pharmacogenomics J 2002;2:20-24.
19. Holtzmann NA: Clinical utility of pharmacogenetics and pharmacogenomics; in Rothstein MA (ed): Pharmacogenomics. Social, Ethical, and Clinical Dimensions. Hoboken, Wiley-Liss, 2003, pp 163-185.
20. Melzer D, Detmer D, Zimmern R: Pharmacogenetics and public policy: expert views in Europe and North America. Pharmacogenomics 2003;4:689-691.
21. Schmedders M, van Aken J, Feuerstein G, Kollek R: Individualized pharmacogenetic therapy: a critical analysis. Community Genet 2003;6:114-119.
22. Feuerstein G, Kollek R, Schmedders M, van Aken J: Irreführende Leitbilder. Zum Mythos der Individualisierung durch pharmakogenetische Behandlungskonzepte. Ethik Med 2003;15:77-86.